Navigation Links
FDA approves new skin cancer drug first tested in Arizona by Scottsdale Healthcare and TGen
Date:2/1/2012

SCOTTSDALE, Ariz. Feb 1, 2012 A new skin cancer drug tested for the first time in the world five years ago at the Virginia G. Piper Cancer Center at Scottsdale Healthcare just received expedited approval by the U.S. Food and Drug Administration, a remarkable accomplishment in new drug development.

Vismodegib (GDC-0449) was administered for the first time in the world Jan. 23, 2007, in a phase I clinical trial at Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership with the Translational Genomics Research Institute (TGen). Vismodegib received FDA approval on Jan. 30, 2012. Clinical trials progress through three phases and can take up to 10 years or more to successfully complete.

The drug is the first to receive FDA approval to treat inoperable basal cell carcinoma. Successful early trial results led to a broader subsequent study sponsored by Genentech. Continued positive study results led to Monday's FDA approval for marketing the drug under the name Erivedge.

Vismodegib is used to treat adult patients with advanced basal cell carcinoma, the most common type of skin cancer. It is intended for use in patients with locally advanced basal cell cancer who are not candidates for surgery or radiation and for patients whose cancer has spread to other parts of the body (metastatic), according to the FDA.

Arizona has one of the highest incidences of skin cancer in the world, and in the United States two million new cases of basal cell carcinoma are diagnosed every year. Most instances of basal cell cancer can be effectively treated, but in some cases, the cancer cells spread and develop an aggressive form of the cancer that does not respond to standard surgical treatment.

"Until now, we did not have any treatments that can effectively slow the tumor growth in these patients with advanced skin cancer," said Daniel Von Hoff, MD, lead investigator. Dr. Von Hoff is physician-in-chief at TGen and chief scientific officer at the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, where cancer patients receive treatment with promising new drugs.

"The drug works by inhibiting the Hedgehog pathway that is active in most basal cell cancers, preventing development, growth and survival of certain cancer cells. Results showed a durable clinical benefit tumor shrinkage visible on X-ray or other physical exam or improvement in symptoms without tumor growth," said Glen Weiss, MD, director of Thoracic Oncology at Virginia G. Piper Cancer Center Clinical Trials and Clinical Associate Professor and Translational Physician Scientist at TGen.

Patient response during the clinical trials was assessed through physical examination and imaging. "Integrating genomic data with state-of-the-art clinical and imaging information to develop and apply targeted therapies has certainly taken a major step forward with the encouraging results from the Hedgehog trial," added Ron Korn, MD, a radiologist and medical director of the Virginia G. Piper Cancer Center at Scottsdale Healthcare.

San Francisco-based Genentech developed Vismodegib. Successful results of early clinical trials at the Virginia G. Piper Cancer Center at Scottsdale Healthcare, Johns Hopkins University and Karmanos Cancer Institute were published in the Sept. 17, 2009 New England Journal of Medicine and led to interest in increased access to the drug.

"In some patients there is progression to life-threatening, locally advanced or metastatic tumors. Approved as a pill to be taken once a day, we believe this new drug represents an opportunity to improve quality of life for these patients," said Dr. Weiss.


'/>"/>
Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. FDA Approves First Combo Drug for Diabetes, Cholesterol
2. FDA Approves Novel Melanoma Drug
3. FDA Approves Blood Thinner Brilinta for Heart Patients
4. FDA Approves Test That Spots Aggressive Breast Cancer
5. FDA Approves Test That Spots HER2-Positive Breast Cancers
6. FDA Approves Another New Drug to Fight Hepatitis C
7. FDA approves new drug for advanced melanoma
8. FDA approves ipilimumab, an immunotherapy, to treat metastatic melanoma
9. FDA Approves 1st New Lupus Drug in More Than 50 Years
10. FDA Approves First 3D Mammogram Device
11. FDA Approves First Pacemaker Deemed Safe During MRIs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... , ... February 17, 2017 , ... ... Chief Executive Officer, George Rogers, was named to Staffing Industry Analysts' 2017 "Staffing ... 100 honors those who have made notable contributions to the staffing industry over ...
(Date:2/17/2017)... CO (PRWEB) , ... February 17, 2017 , ... Top ... annual International Healing NET Foundation Summit from February 21 - 23 in Beaver Creek, ... Foundation (HNF). This marks the Summit’s second year in Beaver Creek, hosting over 60 ...
(Date:2/16/2017)... New York, New York (PRWEB) , ... February ... ... hard work and determination. After what took over 10 years of research, development ... disruptive technology, NTX Technology™. NTX Technology™ is a patented compound of FDA approved ...
(Date:2/16/2017)... , ... February 17, 2017 , ... ... and financial planning services to families and entrepreneurs in the Birmingham area, is ... adoptive mother who needs assistance with her medically challenged son, Anius. , Anius ...
(Date:2/16/2017)... ... 2017 , ... PRESS RELEASE, FOR IMMEDIATE RELEASE:, CONTACT:, David ... Doege is excited to announce the launch of Doege Development, LLC, a Phoenix-based ... build, and site improvements. , Mr. Doege says, "I am so excited to ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... Maine and SCOTTSDALE, Ariz. , ... Health Information Exchange (HIE), announced today it is ... medicine platform. HealthInfoNet,s HIE contains 98% of all ... all Maine hospitals and over 500 ... Board of Directors, HealthInfoNet plans to deploy Orion Health,s ...
(Date:2/16/2017)... LONDON , February 16, 2017 ... die Verbesserung der Wettbewerbsfähigkeit haben in der Medizinproduktebranche ... richtet die globale Medizinproduktebranche den Blick auf unmittelbar ... die bevorstehende Implementierung in diesen Regionen. ... ...
(Date:2/16/2017)... , Feb. 16, 2017 OTTO Health LLC ... of Product Evan Frankel will speak at the ... on Feb. 19–23, 2017 in Orlando, Fla. ... Use Telehealth as a Tool for Network Management " during ... The 2017 HIMSS Annual Conference & Exhibition brings together ...
Breaking Medicine Technology: